MultimediaApril 08, 2021
Yaron Conforti on Psychedelic Medicine Today and 10 Years from Now
Novamind CEO talks with PsyFi about the future of healthcare and the spectrum of alternative services available today in our clinics.
Dr. Reid Robison on How Psychedelic Healing Works and Who Benefits From It
Novamind’s CMO talks with Mark Novak about the potential long-term effects of using psychedelics in a therapeutic setting.
Industry NewsApril 07, 2021
Bringing New Hope to a State Struggling with Mental Illness
The Daily Utah Chronicle speaks with Novamind’s CMO, Dr. Reid Robison, on the game-changing effects of psychedelic-assisted therapy.
Industry NewsMarch 25, 2021
Novamind’s Project with Merck Another Example of Its Research Leadership
Up to 80 million people suffer from treatment-resistant depression and we’re proud to work with one of the most recognized pharmaceutical names in the world to study an alternative.
FeaturesMarch 23, 2021
Yaron Conforti Discusses Partnership with Merck for New Treatment-Resistant Depression Trial
Novamind's CEO talks with George Tsiolis from Agoracom about his excitement to advance research for innovative mental health treatments.
FeaturesMarch 19, 2021
Why Merck Chose Novamind for a New Clinical Trial
Our deep experience hosting clinical trials and treating depression drew Merck to test a new drug aimed at treatment-resistant depression.
FeaturesMarch 15, 2021
Yaron Conforti on Democratizing Access to Psychedelic Medicine
CEO and Director Yaron Conforti talks with Paul Austin, founder of Third Wave, about how Novamind provides safe, legal access to psychedelic medicine today.
FeaturesMarch 02, 2021
Dr. Reid Robison on Novamind’s Innovative Approach to Psychedelic Medicine
Novamind’s Chief Medical Officer discusses the growing need for breakthrough mental health treatments and how Novamind is helping to bring psychedelic medicine into everyday healthcare.
